+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

  • PDF Icon

    Report

  • 411 Pages
  • March 2022
  • Region: Global
  • BCC Research
  • ID: 4858751
Description Jump to:

Chronic disease management includes numerous drugs and medical device-based techniques used for the management of various chronic diseases. This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for chronic disease management through various therapeutics and advanced device technologies.

The current report will provide detailed exposure to chronic disease management market. This report analyzes the market trends of chronic disease management with data from 2020, estimates from 2021, projections of compound annual growth rates through 2026 (forecast period 2021 – 2026), and regional markets of the chronic disease management. This report will highlight the current and future market potential of chronic disease management along with a detailed analysis of the competitive environment. Regulatory scenario, drivers, restrains, and opportunities will be covered in the current report. The report also covers market projections for 2026, and market Shares of key market players.

The market has been segmented based on product segment, segment, disease type, treatment provider, and geography. Based on product segment, the market in this report is segmented into pharmaceutical drugs & biologics (drugs and biologics) and medical device technologies and applications (traditional devices and wearable devices and applications). On the basis of disease type the market is segmented into cancer, diabetes, musculoskeletal, cardiovascular, HIV and related conditions, gastro-intestinal, respiratory, neurology, psychiatry, and other disorders. Based on the treatment adherence, the market in this report is segmented into treatment adherence systems and treatment adherence applications (cloud-based). By delivery technology the chronic disease management market is segmented into injectable and parenteral delivery, oral delivery, nasal & pulmonary, transdermal and others. On the basis of treatment provider, the market is segmented into hospitals & others and home care.

The regional market analysis of chronic disease management is also covered in this report. The market has been segmented into various major regions including North America, Europe, Asia-Pacific, and rest of world regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China, and India are going to be covered within the regional segment. For market estimates, data are going to be provided for 2020 because the base year, with estimates for 2021 and forecast value for 2026.





Report Includes:

  • 99 data tables
  • An up-to-date review and analysis of the global market for chronic disease management therapeutics and device technologies
  • Analyses of the global market trends, with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
  • Evaluation and forecast the overall market size, forecasted growth trends, and corresponding market share analysis by product category, disease type, delivery technology, treatment adherence, treatment provider, and region
  • Insight into the current state of chronic diseases and disorders, with an emphasis on advance needle-free drug delivery technologies, diagnostic methods, and smart device technologies that support effective disease state management
  • Regulatory structure for pharmaceuticals and medical devices, pricing and reimbursement structure, marketed and pipeline products, and major developments influencing the market
  • Key merger and acquisition deals, development of commercially viable products and technologies, and other strategic alliances within the industry
  • Profile descriptions of the leading global players including Abbott, AbbVie Inc., Amgen Inc., Bayer AG, Boston Scientific Corp., Dr. Reddy’s Laboratories Ltd., F. Hoffmann, GlaxoSmithKline PLC, Johnson & Johnson, Medtronic, Novartis, Sanofi, Pfizer and Takeda

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • What’s New in the Report?
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst’s Credentials
  • BCC Custom Research

Chapter 2 Summary and Highlights
Chapter 3 Chronic Diseases and Growing Burden on Economy
  • Background of Chronic Diseases
  • Epidemiology and Global Burden
  • Chronic Disease Types
  • Cardiovascular Disease
  • Lifestyle Disorders
  • Cancer
  • Respiratory Disorders
  • Musculoskeletal Disorders
  • Mental/Mood Disorders
  • Gastro-intestinal Disorders
  • Immune Disorders
  • Neurological Disorders
  • Other Chronic Disorders
  • Tobacco Smoking and Chronic Diseases
  • Aging, Gender and Chronic Diseases
  • Global Demographics
  • U.S. Demographics
  • U.S: Gender, Age and Life Expectancy
  • European Demographics
  • Japanese Demographics
  • Current Challenges and Future Directions

Chapter 4 Impact of COVID-19
  • Overview
  • COVID-19 Crisis
  • Impact on Market for Chronic Diseases Management
  • Current Outlook

Chapter 5 Chronic Diseases: Therapeutics
  • Therapeutics and Chronic Diseases
  • Generic Drugs and Chronic Diseases
  • Generic Drugs vs. Branded Drugs
  • Continued Resistance for Generics
  • Biologics and Biosimilars for Immune-Mediated Chronic Diseases
  • Cancer and Targeted Therapy
  • Clinical Need for Therapeutics
  • Therapeutics and Cost Burden
  • Chronic Diseases and Managed Care
  • Key Marketed and Pipeline Products
  • Key Marketed Products
  • Key Pipeline/R&D Products
  • Unmet Need
  • Current Challenges and Future Developments

Chapter 6 Device Technologies and Applications
  • Medical Devices and Chronic Disease Management
  • Clinical and Market Need of Digital Therapeutics
  • Types of Device Technologies
  • Diagnostic and Monitoring Devices
  • Therapeutic Devices and Technologies
  • Key Marketed and R&D/Pipeline Products
  • Diagnostic and Monitoring Devices
  • Therapeutic Devices and Technologies
  • Advantages of Chronic Disease Management via Digital Care
  • Unmet Need
  • Future Developments for Healthcare and Safety Monitoring
  • Current Challenges
  • Future Outlook

Chapter 7 Chronic Diseases: Treatment Adherence Devices and Applications
  • Treatment Nonadherence
  • Market Need for Medication Adherence Systems and Applications
  • Types of Medication Adherence Systems and Applications
  • Hardware-Centric Medication Adherence Systems
  • Medication Adherence Software Applications
  • Key Marketed and Pipeline Products
  • Hardware-Centric Medication Adherence Systems
  • Medication Adherence Software Applications
  • Software and Mobile Application Advantages
  • Interconnectivity of Adherence App
  • Effectiveness of Smartphone Adherence Apps
  • Current Challenges
  • Future Developments

Chapter 8 Market Size and Growth Analysis
  • Market Size and Growth Analysis
  • Market Size and Growth Analysis by Region
  • Market Size and Growth Analysis by Product Segment
  • Market Size and Growth Analysis by Chronic Disease Type
  • Market Size and Growth Analysis by Treatment Provider and Target Health Settings
  • Market Growth Drivers and Restraints
  • Market Growth Drivers
  • Market Restraints

Chapter 9 Competitive Landscape
Chapter 10 Strategies in the Market for Chronic Disease Management
  • Consolidations
  • Mergers and Acquisitions
  • Recent Mergers and Acquisitions
  • Acquisitions in the Therapeutics (Drugs and Biologics) Space
  • Minority Stakes and Future Options to Acquire
  • Future Strategic Landscape

Chapter 11 Regulatory Structure: Pharmaceuticals and Medical Devices
  • Regulatory Background
  • Regulatory Systems for Medical Devices by Region
  • U.S.
  • European Union
  • Japan
  • Regulatory Systems for Pharmaceuticals by Region
  • U.S.
  • Europe
  • Japan

Chapter 12 Pricing and Reimbursement: Pharmaceuticals and Medical Devices
  • Pricing and Reimbursement Background
  • Pricing and Reimbursement for Medical Devices by Region
  • U.S.
  • Europe
  • Japan
  • Other Asia-Pacific
  • Pricing and Reimbursement for Pharmaceuticals by Region
  • U.S.
  • Europe
  • Japan

Chapter 13 Conclusions - Outlook for Chronic Disease Management
  • Major Developments Influencing the Market
  • Technological Developments
  • Demographic and Economic Trends
  • Changing Structure of the Healthcare Industry
  • Lifestyle Medicine
  • Patient-Centric Programs
  • Long-Term Outlook for Chronic Disease Management

Chapter 14 Company Profiles
  • Top 25 Major Companies
  • ABBOTT
  • ABBVIE INC.
  • AMGEN INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA
  • BAUSCH HEALTH COMPANIES INC.
  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BOSTON SCIENTIFIC CORPORATION
  • BRISTOL-MYERS SQUIBB
  • DR. REDDY’S LABORATORIES LTD.
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON SERVICES INC.
  • LUPIN
  • MEDTRONIC INC.
  • MERCK KGAA
  • NOVARTIS AG
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • SANOFI S.A.
  • TAKEDA PHARMACEUTICAL COMPANY LTD.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • VIATRIS INC.
  • Other Players
  • ACADIA PHARMACEUTICAL
  • ACORDA THERAPEUTICS
  • AGENUS
  • ADHERIUM
  • AKRON
  • ALIVECOR
  • AMIKO
  • ANI PHARMACEUTICALS
  • ALKERMES
  • AMNEAL PHARMACEUTICALS
  • ANAVEX LIFE SCIENCES
  • APOTEX
  • ARENA PHARMACEUTICALS
  • ASLAN PHARMACEUTICALS
  • ASAHI KASAI CORP.
  • ASPEN PHARMACARE
  • ATHERSYS
  • AXSOME THERAPEUTICS
  • BEIGENE
  • BIOXCEL THERAPEUTICS
  • BIOSENSICS
  • BIOSERENITY
  • BIOTRONIK
  • BIOTRICITY
  • BTS BIOENGINEERING
  • CHUGAI PHARMACEUTICALS CO., LTD.
  • CIPLA
  • CLOVIS ONCOLOGY
  • CONNECTEDHEALTH PTE. LTD.
  • CORBUS PHARMACEUTICALS
  • CSPC PHARMACEUTICAL GROUP
  • DAIICHI SANKYO
  • EARLYSENSE
  • EDWARDS LIFESCIENCES CORP.
  • ELI LILLY
  • EMPATICA
  • ENDO INTERNATIONAL
  • ENDOCEUTICS INC.
  • ERYTECH PHARMA
  • ESTEVE
  • EVERIST HEALTH
  • GLOOKO INC.
  • HALOZYME THERAPEUTICS
  • HIKMA PHARMACEUTICALS
  • HOCOMA
  • IHEALTH
  • INFOBIONIC INC.
  • INSULET CORP.
  • INTELESENS
  • INTRA-CELLULAR THERAPIES
  • IOVANCE BIOTHERAPEUTICS
  • IPSEN S.A.
  • JAN MEDICAL INC.
  • JIANGSU HENGRUI MEDICINE
  • LUNDBECK
  • KYOWA HAKKO KIRIN
  • LES LABORATOIRES SERVIER
  • MALLINCKRODT PLC
  • MEDMINDER
  • MENARINI
  • MITSUBISHI TANABE PHARMA
  • NEMAURA MEDICAL INC.
  • NEOFECT CO., LTD.
  • NEUROCRINE BIOSCIENCES
  • NEUROMETRIX INC.
  • NOVO NORDISK
  • NUCANA
  • OMADA HEALTH INC.
  • OMRON CORP.
  • OMNICELL INC.
  • ONO PHARMACEUTICAL CO., LTD.
  • ORION PHARMA LTD.
  • PACIRA PHARMACEUTICALS INC.
  • PHILOSYS
  • POLAR ELECTRO OY
  • PREVENTICE INC.
  • PRESCRIBEWELLNESS LLC
  • PROPELLER HEALTH
  • QARDIO
  • REHAB-ROBOTICS (A MEMBER OF VINCENT MEDICAL HOLDINGS)
  • SAGE THERAPEUTICS
  • SAREPTA THERAPEUTICS
  • SENSE4CARE
  • SHANGHAI PHARMACEUTICALS HOLDING
  • SHIONOGI AND CO., LTD.
  • STADA ARZNEIMITTEL AG
  • SUMITOMO DAINIPPON PHARMA CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES
  • TAISHO PHARMACEUTICAL
  • TCR2 THERAPEUTICS
  • TYME TECHNOLOGIES
  • VERTEX PHARMACEUTICAL
  • VITAL CONNECT
  • WEST PHARMACEUTICAL SERVICES INC.
  • WINMEDICAL SRL
  • YPSOMED HOLDING AG
  • ZOGENIX INC.
  • ZYDUS CADILA

Chapter 15 Appendix A: List of Acronyms
Chapter 16 Appendix B: Professional Organizations
  • American Heart Association
  • American Diabetes Association
  • American Lung Association
  • Infectious Diseases Society of America (IDSA)
  • National Foundation for Infectious Diseases
  • Center for Drug Evaluation and Research (CDER)
  • Center for Devices and Radiological Health (CDRH)
  • Centers for Medicare and Medicaid Services (CMS)
  • European Databank for Medical Devices (EUDAMED)
  • Food and Drug Administration (FDA or USFDA)
  • Hormone Foundation
  • International Diabetes Federation (IDF)
  • International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
  • Network for Excellence in Health Innovation (NEHI)
  • National Center for Biotechnology Information (NCBI)
  • National Institute of Aging (NIA)
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • World Cancer Research Fund International
  • World Health Organization (WHO)

List of Tables
Summary Table : Overall Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Region, Through 2026
Table 1 : Global Death Share, by Various Chronic Disease Types, 2018
Table 2 : Global DALYs Share, by Various Chronic Disease Types, 2018
Table 3 : Global Incidence Share of Hypertension, by Patient Group Type, 2018
Table 4 : Global Prevalence of Angina Pectoris and Stroke (Survivors), Through 2030
Table 5 : Global Incidence and Prevalence of all Stroke Types, 2019
Table 6 : Global Prevalence of Congestive Heart Failure and Stroke, Through 2030
Table 7 : Structural Heart Disease: Management Through Medication
Table 8 : BMI Calculation
Table 9 : BMI Categories Based on Increasing Health Risks
Table 10 : Trends in Obesity Composition of the World’s Population, Through 2025
Table 11 : U.S. Obesity and Severe Obesity vs. General Population, Through 2025
Table 12 : Global Diabetes Types Share
Table 13 : Global Prevalence of Diabetes, by Type, Through 2040
Table 14 : Global Prevalence of Breast Cancer, by Country/Region, Through 2025
Table 15 : Global Epidemiology of Colorectal Cancer, by Region, Through 2030
Table 16 : Prevalence of Multiple Sclerosis by Region, 2013 and 2020
Table 17 : Global Deaths, by Various Types of Cancer, Through 2030
Table 18 : Estimated Global Death Share, by Various Cancer Types, 2021
Table 19 : Global Prevalence of Symptomatic Key Musculoskeletal Disorders, Through 2025
Table 20 : Global Deaths, by Various Musculoskeletal Disorders, Through 2030
Table 21 : Global Deaths from Digestive Diseases, by Region, Through 2025
Table 22 : Global HIV Epidemic, By Age Group, 2020
Table 23 : Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
Table 24 : World Population, by Selected Region, Through 2030
Table 25 : U.S. Population Estimates and Projections, by Age Group, Through 2030
Table 26 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, Through 2020
Table 27 : European Population Estimates and Projections, by Age Group, Through 2030
Table 28 : Japanese Population Estimates and Projections, by Age Group, Through 2030
Table 29 : Key Marketed Respiratory Disorder Therapeutics
Table 30 : Key Marketed Mood Disorder Therapeutics
Table 31 : Key Marketed Musculoskeletal Disorder Therapeutics
Table 32 : Key Marketed Neurovascular Disease Therapeutics
Table 33 : Key Marketed Immune Disorder Therapeutics
Table 34 : Key Marketed Diabetes Therapeutics
Table 35 : Key Marketed Cardiovascular Disease Therapeutics
Table 36 : Key Marketed GI Disorder Therapeutics
Table 37 : Key Marketed Cancer Therapeutics
Table 38 : Key Pipeline/R&D Products: Cancer Therapeutics
Table 39 : Key Pipeline/R&D Products: Neurological Disorder Therapeutics
Table 40 : Key Pipeline/R&D Products: Cardiovascular Disease Therapeutics
Table 41 : Key Pipeline/R&D Products: GI Disorder Therapeutics
Table 42 : Key Pipeline/R&D Products: Musculoskeletal Disorder Therapeutics
Table 43 : Key Pipeline/R&D Products: Diabetes Therapeutics
Table 44 : Key Pipeline/R&D Products: Mood Disorder Therapeutics
Table 45 : Key Marketed and Pipeline/R&D Devices: Cardiac Monitoring Devices and Technologies
Table 46 : Key Marketed and Pipeline/R&D Devices: Continuous Glucose Monitoring Devices and Technologies
Table 47 : Key Marketed and Pipeline/R&D Devices: Sleep-Monitoring Devices and Technologies
Table 48 : Key Marketed and Pipeline/R&D Devices: Vital Sign and Activity Monitoring Devices and Technologies
Table 49 : Key Marketed and Pipeline/R&D Devices: Pain Management Devices and Technologies
Table 50 : Key Marketed and Pipeline/R&D Devices: Drug Delivery Devices and Technologies
Table 51 : Smart Pills for Patient Monitoring
Table 52 : Smart Pills for Oral Drug Delivery
Table 53 : Key Marketed and Pipeline/R&D Devices: Insulin delivery Devices and Technologies
Table 54 : Global Medication Adherence Percentages, by Chronic Diseases
Table 55 : Automated Medication Dispensing Cabinets
Table 56 : Smart Pill Dispensers, Pillboxes and Organizers
Table 57 : Medication Tracking Devices and Apps
Table 58 : Pill Organizer and Reminder Systems
Table 59 : Smart Pill Cap and Bottle Systems
Table 60 : Other Medication Adherence Solutions
Table 61 : Health and Medication Reminder Apps
Table 62 : Personalized Medication Adherence and Text Messaging Apps
Table 63 : Health and Medication Monitoring Apps
Table 64 : Cloud-Based Adherence Solutions and Databases
Table 65 : Health and Medication Adherence Apps
Table 66 : Other Medication adherence Apps
Table 67 : Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Region, Through 2026
Table 68 : Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Product Segment, Through 2026
Table 69 : Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Disease Type, Through 2026
Table 70 : Global Diabetes Estimates and Projections, 2019-2045
Table 71 : Key Strategic Deals in the Chronic Disease Management and Device Technology Market, 2012-2019
Table 72 : Key Strategic Deals in Chronic Disease Management Therapeutics Market, 2016-2021
Table 73 : Key Strategic Deals for Business Units, Minority Stakes and Future Options to Acquire in the Chronic Disease Management Market, 2016-2019
Table 74 : Differences in Regulatory Approval in the U.S. and Europe
Table 75 : Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2015-2018
Table 76 : Abbott: Key Developments
Table 77 : AbbVie Inc.: Key Developments
Table 78 : Amgen Inc.: Key Developments
Table 79 : Astellas Pharma Inc.: Key Developments
Table 80 : AstraZeneca PLC: Key Developments
Table 81 : Bayer AG: Key Developments
Table 82 : Boehringer Ingelheim: Key Developments
Table 83 : Boston Scientific Corp.: Key Developments
Table 84 : Bristol-Myers Squibb Company: Key Developments
Table 85 : Dr. Reddy’s Laboratories Ltd.: Key Developments
Table 86 : F. Hoffmann-La Roche Ltd: Key Developments
Table 87 : Gilead Sciences Inc.: Key Developments
Table 88 : Johnson & Johnson Services Inc.: Key Developments
Table 89 : Lupin: Key Developments
Table 90 : Medtronic: Key Developments
Table 91 : Novartis AG: Key Developments
Table 92 : Otsuka Holdings Co., Ltd.: Key Developments, 2020
Table 93 : Pfizer Inc.: Key Developments
Table 94 : Sanofi S.A.: Key Developments
Table 95 : Takeda: Key Developments
Table 96 : Teva: Key Developments
Table 97 : Viatris: Key Developments
Table 98 : List of Acronyms Used in Chronic Disease Management
List of Figures
Summary Figure : Overall Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Region, 2019-2026
Figure 1 : Global Death Share, by Various Chronic Disease Types, 2018
Figure 2 : Global DALYs Share, by Various Chronic Disease Types, 2018
Figure 3 : Global Incidence of Hypertension, by Patient Group Type, 2018
Figure 4 : Global Prevalence of Angina Pectoris and Stroke (Survivors), 2004-2030
Figure 5 : Global Prevalence of Congestive Heart Failure and Stroke, 2004-2030
Figure 6 : Trends in Obesity Composition of the World’s Population, 2012-2025
Figure 7 : U.S. Obesity and Severe Obesity vs. General Population, 2018-2025
Figure 8 : Global Diabetes Types Share
Figure 9 : Global Prevalence of Diabetes, by Type, 2018-2040
Figure 10 : Global Prevalence of Breast Cancer, by Region/Country, 2015-2025
Figure 11 : Global Epidemiology of Colorectal Cancer, by Region, 2000-2030
Figure 12 : Global Deaths, by Various Cancer Types, 2000-2030
Figure 13 : Estimated Global Death Share, by Various Cancer Types, 2021
Figure 14 : Global Prevalence of Symptomatic Key Musculoskeletal Disorders, by Region, 2018
Figure 15 : Global Death Share, by Various Musculoskeletal Disorders, 2015
Figure 16 : Global Deaths from Digestive Diseases, by Region, 2018-2025
Figure 17 : Global Shares of Key Wound Types, 2020
Figure 18 : Estimated World Population and Annual Growth, by Selected Age Group, 2000-2030
Figure 19 : World Population, by Selected Region, 2000-2030
Figure 20 : U.S. Population Estimates and Projections, by Age Group, 2000-2030
Figure 21 : Estimates of Anticipated U.S. Life Expectancy at Birth, by Gender, 2005-2020
Figure 22 : European Population Estimates and Projections, by Age Group, 2000-2030
Figure 23 : Japanese Population Estimates and Projections, by Age Group, 2000-2030
Figure 24 : Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Region, 2019-2026
Figure 25 : Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Product Segment, 2019-2026
Figure 26 : Global Market Shares of Therapeutics, by Pharmaceutical Drug and Biologic, 2020
Figure 27 : Global Market Shares of Therapeutics, by Delivery Technology, 2020
Figure 28 : Global Market Shares of Device Technologies, by Device Type, 2020
Figure 29 : Global Market for Chronic Disease Management Therapeutics and Device Technologies, by Disease Type, 2019-2026
Figure 30 : Global Market Shares of Therapeutics and Device Technologies, by Treatment Provider and Target Health Settings, 2020
Figure 31 : Global Market Shares of Chronic Disease Management Therapeutics, by Leading Company, 2020
Figure 32 : Global Market Shares of Chronic Disease Management Device Technologies, by Leading Company, 2020
Figure 33 : Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2015-2018
Figure 34 : Abbott: Annual Revenue, 2018-2020
Figure 35 : Abbott: Revenue Share, by Business Segment, 2020
Figure 36 : AbbVie Inc.: Annual Revenue, 2018-2020
Figure 37 : Amgen Inc.: Annual Revenue, 2018-2020
Figure 38 : Amgen Inc.: Revenue Shares, by Product Sales, 2020
Figure 39 : Astellas Pharma Inc.: Annual Revenue, 2018-2020
Figure 40 : Astellas Pharma Inc.: Revenue Shares, by Product Sales, 2020
Figure 41 : AstraZeneca PLC: Annual Revenue, 2018-2020
Figure 42 : AstraZeneca PLC: Revenue Share, by Therapy Areas, 2020
Figure 43 : Bausch Health Companies Inc.: Annual Revenue, 2018-2020
Figure 44 : Bausch Health Companies Inc.: Revenue Share, by Business Segment, 2020
Figure 45 : Bayer AG: Annual Revenue, 2018-2020
Figure 46 : Bayer AG: Revenue Share, by Business Segment, 2020
Figure 47 : Boehringer Ingelheim: Annual Revenue, 2018-2020
Figure 48 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2020
Figure 49 : Boston Scientific Corp.: Annual Revenue, 2018-2020
Figure 50 : Boston Scientific Corp.: Revenue Share, by Business Segment, 2020
Figure 51 : Bristol-Myers Squibb Co.: Annual Revenue, 2018-2020
Figure 52 : Dr. Reddy’s Laboratories Ltd.: Annual Revenue, 2018-2020
Figure 53 : Dr. Reddy’s Laboratories Ltd.: Revenue Share, by Business Segment, 2020
Figure 54 : F. Hoffmann-La Roche Ltd: Annual Revenue, 2018-2020
Figure 55 : F. Hoffmann-La Roche Ltd: Revenue Share, by Division, 2020
Figure 56 : Gilead Sciences Inc.: Annual Revenue, 2018-2020
Figure 57 : Gilead Sciences Inc.: Revenue Share, by Products Sales, 2020
Figure 58 : GlaxoSmithKline PLC: Annual Revenue, 2018-2020
Figure 59 : GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2020
Figure 60 : Johnson & Johnson Services Inc.: Annual Revenue, 2018-2020
Figure 61 : Johnson & Johnson Services Inc.: Revenue Share, by Business Segment, 2020
Figure 62 : Lupin: Annual Revenue, 2018-2020
Figure 63 : Medtronic: Annual Revenue, 2018-2020
Figure 64 : Medtronic: Revenue Share, by Business Segment, 2020
Figure 65 : Merck KGaA: Annual Revenue, 2018-2020
Figure 66 : Merck KGaA: Revenue Share, by Business Segment, 2020
Figure 67 : Novartis AG: Annual Revenue, 2018-2020
Figure 68 : Novartis AG: Revenue Share, by Division, 2020
Figure 69 : Otsuka Holdings Co., Ltd.: Annual Revenue, 2018-2020
Figure 70 : Otsuka Holdings Co., Ltd.: Revenue, by Segment, 2020
Figure 71 : Pfizer Inc.: Annual Revenue, 2018-2020
Figure 72 : Sanofi S.A.: Annual Revenue, 2018-2020
Figure 73 : Sanofi S.A.: Revenue Share, by Business Unit, 2020
Figure 74 : Takeda: Annual Revenue, 2018-2020
Figure 75 : Takeda: Revenue Share, by Therapeutic Areas, 2020
Figure 76 : Teva: Annual Revenue, 2018-2020
Figure 77 : Viatris: Annual Revenue, 2018-2020
Figure 78 : Viatris: Revenue Share, by Product Category, 2020

Executive Summary

This market growth is fueled by a growing geriatric population, changing lifestyles, increasing prevalence of chronic diseases, superior clinical results of new drugs and biologics, and the increasing trend of digital health in the U.S.

Patient Protection and Affordable Care Act, increasing awareness in the developed world, strong research and development (R&D) initiatives from key market players, increasing government initiatives, patient assistance programs, regulatory efforts to provide smooth regulatory approval process, adoption of portable/wearable device technologies and adoption of advanced software applications; further, key drivers for the market include smart pills, targeted therapy, advanced needle-free drug delivery technologies, drug-device combinations and development of home-care and self-medication devices. However, some of the key market barriers are lack of awareness in underdeveloped countries, poor medication adherence, patent expiry blockbuster drugs and biologics, shorter product life cycles for device technologies, regulatory issues (stringent regulatory approval procedure), increasing R&D cost, health disparities in low-income countries, higher cost of the cancer treatment, data privacy, data security and data accuracy.

Regionally, the U.S. is expected to maintain dominance in the therapeutics and device technologies segments of the global chronic disease management market. Those wishing to invest in the chronic disease management therapeutics and device technologies market ought to strongly consider high-growth areas such as pharmaceutical drugs, biologics, medical device technologies and software applications.

Companies Mentioned

  • Abbott
  • Abbvie Inc.
  • Acadia Pharmaceutical
  • Acorda Therapeutics
  • Adherium
  • Agenus
  • Akron
  • Alivecor
  • Alkermes
  • Amgen Inc.
  • Amiko
  • Amneal Pharmaceuticals
  • Anavex Life Sciences
  • Ani Pharmaceuticals
  • Apotex
  • Arena Pharmaceuticals
  • Asahi Kasai Corp.
  • Aslan Pharmaceuticals
  • Aspen Pharmacare
  • Astellas Pharma Inc.
  • Astrazeneca
  • Athersys
  • Axsome Therapeutics
  • Bausch Health Companies Inc.
  • Bayer AG
  • Beigene
  • Biosensics
  • Bioserenity
  • Biotricity
  • Biotronik
  • Bioxcel Therapeutics
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb
  • Bts Bioengineering
  • Chugai Pharmaceuticals Co. Ltd.
  • Cipla
  • Clovis Oncology
  • Connectedhealth Pte. Ltd.
  • Corbus Pharmaceuticals
  • Cspc Pharmaceutical Group
  • Daiichi Sankyo
  • Dr. Reddy’S Laboratories Ltd.
  • Earlysense
  • Edwards Lifesciences Corp.
  • Eli Lilly
  • Empatica
  • Endo International
  • Endoceutics Inc.
  • Erytech Pharma
  • Esteve
  • Everist Health
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Glooko Inc.
  • Halozyme Therapeutics
  • Hikma Pharmaceuticals
  • Hocoma
  • Ihealth
  • Infobionic Inc.
  • Insulet Corp.
  • Intelesens
  • Intra-Cellular Therapies
  • Iovance Biotherapeutics
  • Ipsen S.A.
  • Jan Medical Inc.
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson Services Inc.
  • Kyowa Hakko Kirin
  • Les Laboratoires Servier
  • Lundbeck
  • Lupin
  • Mallinckrodt plc
  • Medminder
  • Medtronic Inc.
  • Menarini
  • Merck Kgaa
  • Mitsubishi Tanabe Pharma
  • Nemaura Medical Inc.
  • Neofect Co. Ltd.
  • Neurocrine Biosciences
  • Neurometrix Inc.
  • Novartis AG
  • Novo Nordisk
  • Nucana
  • Omada Health Inc.
  • Omnicell Inc.
  • Omron Corp.
  • Ono Pharmaceutical Co. Ltd.
  • Orion Pharma Ltd.
  • Otsuka Holdings Co. Ltd.
  • Pacira Pharmaceuticals Inc.
  • Pfizer Inc.
  • Philosys
  • Polar Electro Oy
  • Prescribewellness LLC
  • Preventice Inc.
  • Propeller Health
  • Qardio
  • Rehab-Robotics (A Member of Vincent Medical Holdings)
  • Sage Therapeutics
  • Sanofi S.A.
  • Sarepta Therapeutics
  • Sense4Care
  • Shanghai Pharmaceuticals Holding
  • Shionogi and Co. Ltd.
  • Stada Arzneimittel AG
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Sun Pharmaceutical Industries
  • Taisho Pharmaceutical
  • Takeda Pharmaceutical Company Ltd.
  • Tcr2 Therapeutics
  • Teva Pharmaceuticals Industries Ltd.
  • Tyme Technologies
  • Vertex Pharmaceutical
  • Viatris Inc.
  • Vital Connect
  • West Pharmaceutical Services Inc.
  • Winmedical Srl
  • Ypsomed Holding AG
  • Zogenix Inc.
  • Zydus Cadila

Table Information

Report AttributeDetails
No. of Pages411
PublishedMarch 2022
Forecast Period2021 - 2026
Estimated Market Value ( USD ) in 2021 $ 391.8 Billion
Forecasted Market Value ( USD ) by 2026 $ 553 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned123

Related Topics

Related Reports

Disease Management Apps Global Market Report 2024 - Product Image

Disease Management Apps Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Chronic Disease Management Global Market Report 2024 - Product Image

Chronic Disease Management Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Chronic Disease Management Market Report and Forecast 2024-2032 - Product Image

Global Chronic Disease Management Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Global Disease Management Apps Market Size, Share & Industry Trends Analysis Report By Indication (Obesity, Mental Health, Cardiovascular Issues, Diabetes and Others), By Device, By Platform Type, By Regional Outlook and Forecast, 2023-2029 - Product Image

Global Disease Management Apps Market Size, Share & Industry Trends Analysis Report By Indication (Obesity, Mental Health, Cardiovascular Issues, Diabetes and Others), By Device, By Platform Type, By Regional Outlook and Forecast, 2023-2029

  • Report
  • 198 Pages
  • Global
From
Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029 - Product Image

Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029

  • Drug Pipelines
  • 139 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.